KRAS and neoplasm: An oncogenic pathway of adenoma-carcinoma with KRAS activation and a loss of function of the tumor-suppressor genes TP53 and p16 has been postulated.[52] Long-term survival may be achieved after complete resection.[53] The IPNB is thought of as a counterpart to the pancreatic intraductal papillary mucinous neoplasm.[54]